Clinical Trials Browser

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Immunoglobulin Light-chain Amyloidosis

Immunoglobulin Light-chain Amyloidosis

Multiple Myeloma

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

Leukemia, Lymphocytic, Chronic, B-Cell

Multiple Myeloma

Clinical Trials

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

CARTITUDE-2

IFm2022-01

aMMbition

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Iber-KDd

Daratumumab in STK11 Mutated NSCLC

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

GMMG-DADA

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

FASTER

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

MASTER-2

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

HD10/DSMMXX